Agilent Technologies Inc (A) Shares Sold by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC decreased its position in shares of Agilent Technologies Inc (NYSE:A) by 0.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,135 shares of the medical research company’s stock after selling 750 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Agilent Technologies were worth $15,278,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Agilent Technologies by 0.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 18,394 shares of the medical research company’s stock worth $1,091,000 after acquiring an additional 149 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Agilent Technologies by 1.6% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 48,835 shares of the medical research company’s stock worth $3,385,000 after acquiring an additional 771 shares in the last quarter. Signature Estate & Investment Advisors LLC boosted its stake in shares of Agilent Technologies by 7.3% during the 4th quarter. Signature Estate & Investment Advisors LLC now owns 11,406 shares of the medical research company’s stock worth $764,000 after acquiring an additional 773 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Agilent Technologies by 4.9% during the 3rd quarter. Nordea Investment Management AB now owns 16,484 shares of the medical research company’s stock worth $1,058,000 after acquiring an additional 774 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. boosted its stake in shares of Agilent Technologies by 1.5% during the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 53,147 shares of the medical research company’s stock worth $3,412,000 after acquiring an additional 800 shares in the last quarter.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $70.00, for a total transaction of $1,573,670.00. Following the transaction, the chief executive officer now owns 327,882 shares of the company’s stock, valued at approximately $22,951,740. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 43,703 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $70.00, for a total value of $3,059,210.00. Following the transaction, the chief executive officer now directly owns 302,837 shares in the company, valued at approximately $21,198,590. The disclosure for this sale can be found here. In the last three months, insiders have sold 197,510 shares of company stock worth $13,922,776.

A has been the topic of a number of recent research reports. Robert W. Baird reaffirmed a “buy” rating and issued a $76.00 target price on shares of Agilent Technologies in a research note on Thursday, January 18th. Barclays reaffirmed a “buy” rating and issued a $74.00 target price on shares of Agilent Technologies in a research note on Monday, January 8th. Deutsche Bank set a $75.00 target price on Agilent Technologies and gave the company a “buy” rating in a research note on Tuesday, November 21st. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research note on Tuesday, October 31st. Finally, Cowen reaffirmed a “hold” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agilent Technologies currently has a consensus rating of “Buy” and a consensus target price of $70.98.

Agilent Technologies Inc (A) opened at $71.97 on Friday. Agilent Technologies Inc has a 52 week low of $50.58 and a 52 week high of $75.00. The firm has a market capitalization of $23,225.94, a price-to-earnings ratio of 28.79, a price-to-earnings-growth ratio of 2.10 and a beta of 1.28. The company has a current ratio of 3.23, a quick ratio of 2.85 and a debt-to-equity ratio of 0.40.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.08. Agilent Technologies had a return on equity of 17.70% and a net margin of 4.25%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the company posted $0.53 EPS. sell-side analysts expect that Agilent Technologies Inc will post 2.67 earnings per share for the current year.

WARNING: This piece was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/02/18/agilent-technologies-inc-a-shares-sold-by-clifford-swan-investment-counsel-llc.html.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply